Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update

IMMUNIC, INC. (IMUX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update – Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Remain on Track, with Top-Line Data Expected in December 2026 – – Initiatio

Event · Earnings
Original reporting
Published Nov 13, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 1:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IMUX
Neutral
high confidence
Mentioned
$IMUX
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IMUXNeutralMed
01

Why it matters

The disclosure provides the first public timeline for top‑line data, which is a key catalyst for the stock.

02

Market read

Primary catalyst for IMUX; may influence sector sentiment for neurology biotech stocks.

03

What to watch

Execution risk of the upcoming NDA filing and competition from other oral MS therapies.

Relevance 8/10Novelty 9/10Timing: today
AlphAI · Earnings readIMUX · Q3 2026 · ended 2026-09-30

Immunic reports Q3 2026 net loss of approximately $42.3 million as R&D and G&A spend rises; ENSURE-1 and ENSURE-2 top-line data still expected December 2026

→Mixed quarter

Clinical-stage company with no revenue reported in the filing. Net loss and operating expenses rose sharply year over year, with G&A up on a non-cash separation-related charge. Cash of $132.0 million is said to fund operations into late 2027, and the Phase 3 ENSURE readout is expected in December 2026, so the period's results mainly set up pending catalysts.

EPS · GAAP
$(0.99)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total operating expenses, three months ended Sep 30, 2026GAAP$43.4M––
Total operating expenses, nine months ended Sep 30, 2026GAAP$111.9M––
Non-cash charges included in operating expenses, three months ended Sep 30, 2026other$13.9M––
Non-cash charges included in operating expenses, nine months ended Sep 30, 2026other$25.2M––
Research and development expenses, three months ended Sep 30, 2026GAAP$23.9M–$3.9 million increase
Research and development expenses, nine months ended Sep 30, 2026GAAP$75.5M–$12.6 million increase
General and administrative expenses, three months ended Sep 30, 2026GAAP$19.4M–$13.4 million increase
General and administrative expenses, nine months ended Sep 30, 2026GAAP$36.4M–$19.4 million increase
Loss from operations, three months ended Sep 30, 2026GAAP−$43.37M––
Loss from operations, nine months ended Sep 30, 2026GAAP−$111.9M––
Interest income, three months ended Sep 30, 2026GAAP$1.1M–$0.7 million increase
Interest income, nine months ended Sep 30, 2026GAAP$3.1M–$2.3 million increase
Other income (expense), net, three months ended Sep 30, 2026GAAP$(0.03 million)––
Other income (expense), net, nine months ended Sep 30, 2026GAAP$(0.2 million)–$1.4 million decrease
Total other income, three months ended Sep 30, 2026GAAP$1.06M––
Total other income, nine months ended Sep 30, 2026GAAP$2.94M––
Net loss, three months ended Sep 30, 2026GAAPapproximately $42.3 million––
Net loss, nine months ended Sep 30, 2026GAAPapproximately $109.0 million––
Net loss per share, basic and diluted, three months ended Sep 30, 2026GAAP$(0.99)––
Net loss per share, basic and diluted, nine months ended Sep 30, 2026GAAP$(2.83)––
Cash and cash equivalents as of Sep 30, 2026other$132M––
Total assets as of Sep 30, 2026GAAP$136.4M––
Total stockholders' equity as of Sep 30, 2026GAAP$104.5M––

Capital returns

  • No share repurchases or dividends are reported in the filing.
  • The filing references a February 2026 Private Placement, which the company cites as the reason for higher average cash balances and interest income. Balance sheet common shares rose to 15,880,822 at Sep 30, 2026 from 12,038,263 at Dec 31, 2025.

What drove it

  • R&D rose $3.9 million in the quarter. The company attributes the increase to a $1.9 million rise in personnel expenses, a $1.4 million rise for vidofludimus calcium drug supply, a $2.9 million rise for NDA readiness activities, a $0.3 million rise for drug-drug interaction studies and a $0.2 million rise across other categories. It partly offsets these with a $1.8 million decrease related to the ENSURE clinical trials and a $1.0 million decrease related to the CALLIPER clinical trial.
  • G&A rose $13.4 million in the quarter. The company attributes $11.0 million to personnel expenses, of which $9.7 million was non-cash stock compensation primarily related to a separation agreement. It also cites $1.3 million for legal and consultancy expenses, $0.6 million for pre-commercial marketing and $0.5 million across other categories.
  • The company states that interest income rose $0.7 million in the quarter due to a higher average cash balance from the February 2026 Private Placement.
  • The company attributes the nine-month decline in other income, net to $1.0 million of German Federal Ministry of Finance grant income recognized in Q1 2025 with no grant income in 2026, and a $0.4 million decrease across various categories.

Concerns

  • Net loss for the quarter was approximately $42.3 million, up from approximately $25.6 million a year earlier, and EPS of $(0.99) compares with $(1.32). The filing reports no revenue line.
  • Operating expenses of $43.4 million for the quarter include $13.9 million of non-cash charges, mainly stock compensation. The company says $9.7 million of the Q3 G&A increase was non-cash stock compensation primarily related to a separation agreement.
  • Cash runway is stated as into late 2027, which is shorter than the timeline for a potential NDA submission in mid-2027 followed by a targeted approval in 2028. The filing acknowledges the need to raise additional capital as a risk.
  • The filing notes that the CALLIPER open-label and post-hoc analyses are exploratory, not placebo-controlled, not validated and, for the preclinical data, not established clinically.

What to watch

  • Top-line data from the Phase 3 ENSURE-1 and ENSURE-2 trials in relapsing MS, expected in December 2026.
  • Whether the company submits an NDA in the United States in mid-2027, as stated in the filing, if ENSURE results are positive.
  • Initiation and first-patient enrollment in the Phase 3 PROTECT-MS trial in progressive MS, expected in the first half of 2027.
  • Trajectory of R&D and G&A spending, including NDA readiness and commercial preparation costs.
  • Cash runway and any need for additional capital, given the stated runway into late 2027.
  • Progress of the preclinical IMU-381 program, where lead candidate identification is ongoing.

Balance sheet and cash flow

  • Cash and cash equivalents of $131,963 thousand at Sep 30, 2026, compared with $15,483 thousand at Dec 31, 2025.
  • Total current assets of $135,087 thousand at Sep 30, 2026, compared with $22,869 thousand at Dec 31, 2025.
  • Total liabilities of $31,950 thousand at Sep 30, 2026, compared with $30,725 thousand at Dec 31, 2025.
  • Accounts payable of $10,120 thousand and accrued expenses of $20,058 thousand at Sep 30, 2026.
  • Additional paid-in capital of $819,290 thousand at Sep 30, 2026, compared with $599,249 thousand at Dec 31, 2025.
  • Accumulated deficit of $(717,567) thousand at Sep 30, 2026, compared with $(608,571) thousand at Dec 31, 2025.
  • Management states that, based on its current operating plan, cash and cash equivalents are expected to fund operations into late 2027. The filing also includes a risk factor on the possibility that cash may be insufficient and that additional capital may need to be raised.
  • No operating cash flow, investing cash flow, financing cash flow or free cash flow figures are printed in the filing.

Analysis

Immunic reported a third-quarter 2026 net loss of approximately $42.3 million, or $(0.99) per basic and diluted share, against approximately $25.6 million, or $(1.32), a year earlier. The filing prints no revenue, cost of sales or gross margin line, so the read is entirely about the cost base and the funding position of a clinical-stage company. Total operating expenses were $43.4 million for the quarter and $111.9 million for the nine months, against $26.0 million and $79.9 million a year earlier. Of the quarterly total, $13.9 million is non-cash, primarily stock compensation.

The cost increase has two distinct sources. R&D rose to $23.9 million from $20.0 million. The company attributes the rise mainly to NDA readiness activities, drug supply for vidofludimus calcium and personnel costs, partly offset by lower spending on the ENSURE and CALLIPER trials. G&A rose to $19.4 million from $6.0 million, and the company ties most of that increase to $9.7 million of non-cash stock compensation primarily related to a separation agreement, with the rest from personnel, legal and consultancy, and pre-commercial marketing. Management therefore frames the G&A step-up as partly one-time in nature, though the filing does not state a run-rate for future G&A.

Below the operating line, interest income rose to $1.1 million from $0.4 million, which the company links to the higher average cash balance after the February 2026 Private Placement. Other income (expense), net was $(0.03) million in the quarter. For the nine months it was $(0.2) million, against $1.2 million a year earlier, a swing the company attributes to grant income recognized in Q1 2025 that did not recur. Because interest income partly offsets the operating loss, the net loss grew by less than the operating loss in the quarter.

On the balance sheet, cash and cash equivalents were $132.0 million at September 30, 2026, up from $15.5 million at December 31, 2025, and total stockholders' equity moved to $104.5 million from a deficit of $(6.7) million. Management says current funds are expected to support operations into late 2027. The filing does not print operating or free cash flow, so the cash consumption rate for the quarter cannot be read directly from the document. Investors should note that the runway ends about a year after the planned NDA submission in mid-2027 and a targeted approval in 2028, so the company's future financing needs depend on the outcome of the ENSURE trials and any financing that follows.

The near-term focus is the top-line ENSURE-1 and ENSURE-2 readout in relapsing MS, expected in December 2026. Management says it will prepare an NDA in the United States if results are positive. The Phase 3 PROTECT-MS trial in progressive MS is expected to enroll its first patient in the first half of 2027. The company's supporting CALLIPER analyses are described as exploratory, post-hoc, open-label or preclinical, and the filing itself cautions that they may not predict confirmatory trial results. The quarter therefore sets up the catalysts rather than delivering a commercial or financial result on its own.

Management, verbatim

We are evolving from a science-driven biotechnology company into a fully integrated commercial organization, with a key focus on understanding and addressing the needs of people living with MS.

Erik Lundgren, Chief Executive Officer

Further, our Phase 3 ENSURE trials in relapsing MS continue to be on track to report top-line data in December 2026.

Michael A. Panzara, M.D., M.P.H., Chief Medical Officer

Not in the filing

stated, not guessed
  • No revenue or sales line is reported in the filing.
  • No cost of sales or gross margin is reported.
  • No prior-year or prior-quarter percentage changes are printed for total operating expenses, operating loss, net loss or EPS.
  • Prior-quarter (Q2 2026) figures are not printed in the filing.
  • Cash and cash equivalents for the same period in the prior year (Sep 30, 2025) are not printed.
  • Total assets and stockholders' equity for the prior year end on the same basis are not printed; only Dec 31, 2025 balances appear in the balance sheet.
  • No operating, investing or financing cash flow figures are printed.
  • No debt balance or debt disclosure is printed.
  • No quantitative financial guidance (revenue, operating expense or net loss outlook) is provided.
  • No previous-release outlook was provided, so no comparison against prior guidance is possible.
  • No non-GAAP measures or reconciliations are reported.
  • No segment or geographic revenue breakdown is reported.
  • No share-price reaction or analyst consensus figures are in the document.
  • Income tax expense or benefit is not printed.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Immunic, Inc. (Nasdaq: IMUX) filed an 8‑K reporting Q3 2026 results and progress on its Phase 3 MS programs.

Company-level read

Ticker impact

$IMUXNeutralHigh confidence
Context

Q3 2026 financial results and update on Phase 3 ENSURE trials with top‑line data expected in December 2026.

Expected impact

potential upside ahead of the December 2026 readout, with downside risk if data miss expectations

Evidence & confidence

Trial data are material for a late‑stage biotech; investors typically react strongly to Phase 3 outcomes.

Market effects

May lift peer multiple‑sclerosis biotech stocks if data are positive.

Limited to US biotech sector; no broader regional effect.

Relevant to global investors tracking late‑stage neurology therapies.

Counterpoint

If the ENSURE readout disappoints, the stock could see a sharp sell‑off despite prior hype.

Key entities

  • Immunic, Inc.

    Late‑stage biotech developing oral therapies for multiple sclerosis.

  • Erik Lundgren

    CEO of Immunic, quoted on trial progress.

Every IMUX earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

Med

Immunic Releases Q3 2026 Financial Results

Immunic Inc. reported a narrower Q3 2026 loss of $0.99 per share, down 25% from the prior year. The biotech company's net loss was $42.3M, attributed to R&D investments. Analysts remain bullish, with 9 buy and 1 hold rating. The company is developing therapies for chronic inflammatory and autoimmune diseases.

$IMUXMed

Immunic 3Q 2026: EPS ($0.99) — 10-Q Summary

Immunic reported a net loss of $42.3M, up 65% YoY, with operating expenses rising 67%. R&D costs increased 20%, while G&A expenses surged 225% due to personnel costs. Top-line data from Phase 3 trials is expected in December 2026. According to the company, Phase 3 progressive MS trial initiation is ongoing, with first-patient-enrolled expected in the first half of 2027.

$IMUXHigh

Immunic shares fall 5% on third quarter earnings miss

Immunic Inc. (IMUX) reported a Q3 loss of $0.99 per share, missing estimates by $0.05. Shares fell 5.44% premarket. Net loss was $42.3M, up from $25.6M last year, due to higher operating expenses. The company expects top-line data from ENSURE-1 and ENSURE-2 trials in December 2026. Cash reserves are $132.0M, expected to last into late 2027.

$IMUXMedAI 8/10

EQS-News: Immunic AG: Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting

Immunic (IMUX) presented new clinical, biomarker, and preclinical data for vidofludimus calcium at MSToronto2026. Data showed durability of disability outcomes, neuroprotective effects, and reduced EBV-specific T-cell signatures. The company plans to initiate a Phase 3 program in progressive MS and expects top-line results from Phase 3 ENSURE trials by year-end 2026.